secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001823239-23-000087
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q3 revenue down 65% to $66.9M, net loss of $15.1M; cuts ~100 jobs to save $30M annually
--------------------------------------------------------------------------------

- Q3 revenue $66.9M (-65% YoY); net loss $15.1M vs net income $99.7M a year ago.
- Nucleic Acid Production revenue $51.2M (-71% YoY); COVID-19 CleanCap demand fell $111.6M from prior year.
- Cost realignment targets $30M annual savings, workforce reduction of ~15% (~100 employees) with $5M one-time severance.
- Full-year 2023 guidance lowered to revenue $275-285M; Adjusted EBITDA margin 18% in Q3.
- Partnerships with Thermo Fisher, Intellia, Elixirgen, Precision BioSciences for mRNA cap analogs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/0001823239-23-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/mrvi-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001823239-23-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer